Recombinant plasminogen activators: A comparative review of the clinical pharmacology and therapeutic use of alteplase and reteplase

BioDrugs

Volumn 9, Issue 6, 1998, Pages 455-463

  Moser, Martin ^a,b   Kohler, Benedikt ^a   Schmittner, Marc ^a   Bode, Christoph ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b Ludolf Krehl Klinik   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; ANISTREPLASE; HEPARIN; RECOMBINANT PLASMINOGEN ACTIVATOR; RETEPLASE; STREPTOKINASE; UROKINASE;

ACUTE HEART INFARCTION; BLEEDING; BLOOD CLOT LYSIS; BOLUS INJECTION; BRAIN HEMORRHAGE; CLINICAL TRIAL; CONTINUOUS INFUSION; CORONARY ARTERY THROMBOSIS; DRUG EFFICACY; FIBRINOLYTIC THERAPY; HEPARINIZATION; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; REVIEW; STROKE; TREATMENT OUTCOME;

EID: 0031804199     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-199809060-00003     Document Type: Review

References (31)

1. GISSI (Gruppo Italiano per lo Studio della Streptokinasi nell'Infarto myocardico). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1986 Feb 22: 1: 397-402
2. Hoylaerts M, Rijken DC, Lijnen HR, et al. Kinetics of the activation of plasminogen by human tissue plasminogen activator: role of fihrin. J Biol Chem 1982; 257: 2912-9
3. Kohnert U, Rudolph R, Verheijen JH, et al. Biochemical properties of the kringle 2 and protease domains are maintained in the refolded t-PA deletion variant BM 06.022. Protein Eng 1992; 5: 93-100
4. Martin U, Sponer G, Strein K. Differential fibrinolytic properties of the recombinant plasminogen activator BM 06.022 in human plasma and blood clot systems in vitro. Blood Coagul Fibrinol 1993; 4: 235-42
5. Madison EL, Goldsmith EJ, Gerard RD, et al. Serpin-resistant mutants of human tissue type plasminogen activator. Nature 1989; 339: 721-3
6. Martin U, Köhler J, Sponer G, et al. Pharmacokinetics of the novel recombinant plasminogen activator BM 06.022 in rats, dogs, and nonhuman primates. Fibrinolysis 1992; 6: 39-43
7. Seifried E, Mueller M, Martin U, et al. Bolus application of a novel recombinant plasminogen activation in acute myocardial infarction patients: pharmacokinetics and effect on the hemostatic system. Ann NY Acad Sci 1991; 667: 417-20
8. Martin U, Fischer S, Kohnert U, et al. Thrombolysis with an Escherichia coli-produced recombinant plasminogen activator (BM 06.022) in the rabbit model of jugular vein thrombosis. Thromb Haemost 1991; 65: 560-4
9. Martin U, Sponer G, Strein K. Evaluation of thrombolytic and systemic effects of thec novel recombinant plasminogen activator BM 06.022 compared with alteplase, anistreplase, streptokinase, and urokinasc in a canine model of coronary artery thrombosis. J Am Coll Carcdiol 1992; 19: 433-40
10. Martin U, Sponer G, Strein K. Hirudin and solutroban improve coronary blood flow after reperfusion induced by the novel recombinant plasminogen activator BM 06.022 in a canine model of coronary artery thrombosis. J Int Haematol 1992; 56: 143-53
11. TIMI Study Group. The Trombolysis in Myocardial Infarction (TIMI) trial: phase I results N Engl J Med 1985; 312: 932-6
12. Neuhaus KL, von Essen R, Vogt A, et al. Dose finding with a novel recombinant plasminogen activator (BM 06.022) in patients with acute myocardial infarction: results of the German Recombinant Plasminogen Activator Study. J Am Coll Cardiol 1994; 24: 55-60
13. Tebbe U, von Essen R, Smolarz A, et al. Open, non-controlled dose-finding study with a novel plasminogen activator (BM 06.022) given as a double bolus in patients in patients with acute myocardial infarction. Am J Cardiol 1993; 72: 518-24
14. Smalling RW, Bode C, Kalbfleisch J, RAPID Investigators, et al. More rapid, complete, andi stable coronary thrombosis with bolus administration of reteplase compared with alteplase infusion in acute myocardial infarction. Circulation 1995; 91: 2725-32
15. Smalling RW, Bode C, Kalbfleisch J, RAPID Investigators, et al. Improvement of global and regional LV-function by the bolus administration of recombinant plasminogen activator (r-PA) in acute myocardial infarction: a comparison with standard dose alteplase [abstract]. Calculation 1994; 90 Suppl 1: 562
16. Bode C, Smalling RW, Sen S, RAPID Investigators, et al. Safety profile of reteplase (r-PA) as compared to alteplase (rt-PA): will there be fewer strokes [abstract]? Eur Heart J 1994; 15 Suppl.: 3096
17. International Joint Efficacy Comparison of Thrombolytics. Randomized, double-blind comparison of reteplase double bolus administration with streptokinase in acute myocardial infarction (INJECT): trial to investigate equivalence: Lancet 1995; 346: 329-36
18. GUSTO (Global Utilisation of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries). An international randomised trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993; 329: 673-82
19. Bode C, Smalling RW, Berg G, RAPID 2 Investigators, et al. Randomized comparison of coronary thrombolysis achieved with double-bolus rereplase (recombinant plasminogen activator and front-loaded, accelerated alteplase (recombinant tissue plasminogen activator) in patients with acute invocardial infarction. Circulation 1996; 84: 891-8
20. GUSTO-III. A comparison of reteplase with alleplase for acute myocardial infarction. N Engl J Med 1997; 337: 1118-23
21. Carney RJ, Murphy GA, Brand TR, et al. Randomized angiographic trial of recombinant tissue-type plasminogen activator (alteplase) in mycardial infarction. J Am Coll Cardiol 1992; 52: 17-23
22. Neuhaus KL, von Essen R, Tebbe U, et al. Improved thrombolysis in acute myocardial infarction with front-loaded administration of alteplase: results of the rt-PA APSAC patency study (TAPS). J Am Coll Cardiol 1992; 19: 855-91
23. GUSTO Angiographic Investigators. The comparative effects of tissue plasminogen activator, streptokinase, or both on coronary artery patency, ventricular function and survival in acute myocardial infarction. N Engl J Med 1993; 329: 1615-22
24. Vogt A, von Essen R, Tebbe U, et al. Impact of early reperfusion status of the infarct-related artery on short-term mortality aftet thrombolysis for acute myocardial infarction: comparative analysis of four German multicenter studies. J Am Coll Cardiol 1993; 21: 1391-5
25. Karagounis L, Sorensen SG, Menlove RL, TEAM-2 Investigators, et al. Does Thrombolysis In Myocardial Infarction (TIMi) perfusion grade 2 represent a mostly patent artery or a mostly occluded artery? Enzymatic and electrocardiographic evidence from the TEAM-2 study. J Am Coll Cardiol 1992; 19: 1-10
26. Schofer J, Lins M, Mathey DG, et al. Time course of left ventricular function and coronary patency after saruplase vs streptokinase in acute myocardial infarction. Eur Heart J 1993; 14: 958-63
27. Anderson JL, Karanougis LA, Becker LC, TEAM-3 Investigators, et al. TIMI perfusion grade 3 but not grade 2 results in improved outcome after thrombolysis for acute myocardial infarction: ventriculographic, enzymatic, and electrocardiographic evidence from the TEAM-3 study. Circulation 1993; 87: 1829-39
28. Gibson CM, Cannon CP, Piana RN, TIM1-4 Study Group, et al. Consequences of TIMI 2 vs 3 flow at 90 minutes following: thrombolysis [abstract]. J Am Coll Cardiol 1993; 21 Suppl. A: 348A
29. de Bono DP, Simoons ML, Tijssen J European Cooperative Study Group, et al. Effect of early intravenous heparin on coronary patency, infarct size and bleeding complications after alteplase thrombolysis: results of a randomized double blind European Cooperative Study Group trial. Br Heart J 1992; 67: 122-8
30. ISIS-3. A randomized comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41299 cases of suspected acute myocardial infarction. Lancet 1992; 339: 753-770
31. Continuous Infusion versus Double Bolus Administration of Alteplase Investigators. COBALT: a comparison of continuous infusion of alteplase with double-bolus administration for acute myocardial infarction. N Engl J Med 1997; 337: 1124-30